Canadian Sec - Delayed Quote CAD
Rize Oncology Inc. (RIZE.CN)
0.0300
+0.0100
+(50.00%)
At close: May 16 at 9:31:25 AM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Roland Boivin | CEO & Director | 117.69k | -- | 1967 |
| Dr. William James Garner M.D. | Co-Founder & Executive Director | -- | -- | 1966 |
| Dr. R. Geoffrey Sargent Ph.D. | Co-Founder & Chief Scientific Officer | -- | -- | 1955 |
| Mr. Jim O'Neill | Chief Financial Officer | -- | -- | -- |
Rize Oncology Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Rize Oncology Inc. engages in the development of oncology therapeutics. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.
Corporate Governance
Rize Oncology Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available